Loading fund overlap…
33 of 127 unique stocks in common · Jaccard: 26%
A weighted portfolio overlap of 59.48% indicates a moderate overlap (a meaningful shared core). This means that out of every ₹100 you invest across these two schemes, approximately ₹59.48 is allocated to the exact same companies at the same relative proportions. The schemes share 33 common holdings.
The largest overlapping asset in their portfolios is Sun Pharmaceutical Industries, which commands a weight of 13.91% in Back to Index and 13.01% in Kotak Healthcare Fund. Holding both schemes increases your concentration in Sun Pharmaceutical Industries rather than expanding your diversification.
If the overlap is above 30%, it is typically because both schemes benchmark to the same index (e.g. Nifty 50 or Nifty LargeMidcap 250) or overlap in their top large-cap picks. To improve your portfolio's diversification, consider allocating one of these tranches to a category with lower structural correlation (such as a mid-cap, small-cap, or international equity fund).
| Stock | in Back | in Kotak |
|---|---|---|
| Sun Pharmaceutical IndustriesPharmaceuticals & Biotechnology | 13.91% | 13.01% |
| Divi's LaboratoriesPharmaceuticals & Biotechnology | 5.90% | 5.95% |
| Max Healthcare InstituteHealthcare Services | 5.23% | 5.43% |
| CiplaPharmaceuticals & Biotechnology | 5.28% | 5.00% |
| Fortis HealthcareHealthcare Services | 3.43% | 4.31% |
| Apollo Hospitals EnterpriseHealthcare Services | 5.55% | 2.92% |
| LupinPharmaceuticals & Biotechnology | 3.97% | 2.63% |
| Aurobindo PharmaPharmaceuticals & Biotechnology | 2.76% | 2.29% |
| Glenmark PharmaceuticalsPharmaceuticals & Biotechnology | 2.56% | 2.03% |
| Laurus LabsPharmaceuticals & Biotechnology | 3.04% | 1.95% |
| Alkem LaboratoriesPharmaceuticals & Biotechnology | 2.25% | 1.86% |
| Mankind PharmaPharmaceuticals & Biotechnology | 1.78% | 3.18% |
| Zydus LifesciencesPharmaceuticals & Biotechnology | 1.60% | 1.35% |
| JB Chemicals & PharmaceuticalsPharmaceuticals & Biotechnology | 1.22% | 6.23% |
| Krishna Institute Of Medical SciencesHealthcare Services | 1.18% | 3.12% |
| Sai Life SciencesPharmaceuticals & Biotechnology | 1.03% | 2.90% |
| Gland PharmaPharmaceuticals & Biotechnology | 0.99% | 2.01% |
| Acutaas ChemicalsPharmaceuticals & Biotechnology | 0.95% | 4.92% |
| Ajanta PharmaPharmaceuticals & Biotechnology | 0.85% | 2.20% |
| Dr. Lal Path LabsHealthcare Services | 0.75% | 1.26% |
| Jubilant PharmovaPharmaceuticals & Biotechnology | 0.53% | 2.40% |
| Rainbow Childrens MedicareHealthcare Services | 0.45% | 1.48% |
| Emcure PharmaceuticalsPharmaceuticals & Biotechnology | 0.41% | 1.51% |
| Metropolis HealthcareHealthcare Services | 0.36% | 1.09% |
| Anthem BiosciencesPharmaceuticals & Biotechnology | 0.33% | 2.44% |
| Marksans PharmaPharmaceuticals & Biotechnology | 0.33% | 2.20% |
| Yatharth Hospital And Trauma Care ServicesHealthcare Services | 0.25% | 1.28% |
| Rubicon ResearchPharmaceuticals & Biotechnology | 0.17% | 1.80% |
| Innova CaptabsPharmaceuticals & Biotechnology | 0.09% | 1.17% |
| Orchid PharmaPharmaceuticals & Biotechnology | 0.07% | 1.70% |
| Park Medi World Limited (Park Hospital)Healthcare Services | 0.06% | 4.20% |
| Corona RemediesPharmaceuticals & Biotechnology | 0.05% | 1.65% |
| Laxmi DentalHealthcare Equipment & Supplies | 0.03% | 1.18% |
Weighted overlap = Σ min(weight in fund A, weight in fund B) across shared stocks, from each fund's latest public monthly portfolio (as on May 2026). Equity holdings only, ISIN-verified. Not investment advice.